Transactions with shares and linked securities in Genmab A/S made by managerial employees and their closely associated persons
02 März 2024 - 12:04AM
Transactions with shares and linked securities in Genmab A/S made
by managerial employees and their closely associated persons
Company Announcement
COPENHAGEN, Denmark; March 02, 2024 –
Genmab A/S (Nasdaq: GMAB) - In accordance
with Article 19 of Regulation No. 596/2014 on Market Abuse and
Implementing Regulation 2016/523, this document discloses the data
of the transactions made in Genmab A/S (Nasdaq: GMAB) by managerial
employees and their closely associated persons.
The company’s managerial employees and their closely
associated persons have given Genmab A/S power of attorney on their
behalf to publish trading in Genmab shares by the company’s
managerial employees and their closely associated
persons.
This company announcement includes the vesting and net
settlement of the restricted stock units granted to Jan van de
Winkel and Anthony Pagano on February 26, 2021.
Please find below a statement of such trading in shares
issued by Genmab A/S
1. |
Details of the person discharging managerial
responsibilities / person closely associated |
a) |
Name |
Jan van de Winkel |
2. |
Reason for the notification |
a) |
Position/status |
President & Chief Executive Officer |
b) |
Initial notification/Amendment |
Initial notification |
3. |
Details of the issuer, emission allowance market
participant, auction platform, auctioneer or auction
monitor |
a) |
Name |
Genmab A/S |
b) |
LEI-code |
529900MTJPDPE4MHJ122 |
4. |
Details of the transaction(s): section to be repeated for
(i) each type of instrument; (ii) each type of transaction; (iii)
each date; and (iv) each place where transactions have been
conducted |
a) |
Description of the financial instrument, type of instrument
Identification code |
Share DK0010272202 |
b) |
Nature of the transaction |
Acquisition due to vesting of restricted stock units |
c) |
Price(s) and volume(s) |
Price(s) |
Volume(s) |
|
|
DKK 0.00 |
5,630 |
d) |
Aggregated information - Aggregated volume - Price |
|
e) |
Date of the transaction |
2024-03-01 |
f) |
Place of the transaction |
Outside a market place |
|
|
|
|
|
1. |
Details of the person discharging managerial
responsibilities / person closely associated |
a) |
Name |
Anthony Pagano |
2. |
Reason for the notification |
a) |
Position/status |
Executive Vice President & Chief Financial Officer |
b) |
Initial notification/Amendment |
Initial notification |
3. |
Details of the issuer, emission allowance market
participant, auction platform, auctioneer or auction
monitor |
a) |
Name |
Genmab A/S |
b) |
LEI-code |
529900MTJPDPE4MHJ122 |
4. |
Details of the transaction(s): section to be repeated for
(i) each type of instrument; (ii) each type of transaction; (iii)
each date; and (iv) each place where transactions have been
conducted |
a) |
Description of the financial instrument, type of instrument
Identification code |
Share DK0010272202 |
b) |
Nature of the transaction |
Acquisition due to vesting of restricted stock units |
c) |
Price(s) and volume(s) |
Price(s) |
Volume(s) |
|
|
DKK 0.00 |
2,437 |
d) |
Aggregated information - Aggregated volume - Price |
|
e) |
Date of the transaction |
2024-03-01 |
f) |
Place of the transaction |
Outside a market place |
|
|
|
|
|
1. |
Details of the person discharging managerial
responsibilities / person closely associated |
a) |
Name |
Martin Schultz |
2. |
Reason for the notification |
a) |
Position/status |
Member of the Board of Directors |
b) |
Initial notification/Amendment |
Initial notification |
3. |
Details of the issuer, emission allowance market
participant, auction platform, auctioneer or auction
monitor |
a) |
Name |
Genmab A/S |
b) |
LEI-code |
529900MTJPDPE4MHJ122 |
4. |
Details of the transaction(s): section to be repeated for
(i) each type of instrument; (ii) each type of transaction; (iii)
each date; and (iv) each place where transactions have been
conducted |
a) |
Description of the financial instrument, type of instrument
Identification code |
Share DK0010272202 |
b) |
Nature of the transaction |
Acquisition due to vesting of restricted stock units(as employee of
Genmab A/S) |
c) |
Price(s) and volume(s) |
Price(s) |
Volume(s) |
|
|
DKK 0.00 |
211 |
d) |
Aggregated information - Aggregated volume - Price |
|
e) |
Date of the transaction |
2024-03-01 |
f) |
Place of the transaction |
Outside a market place |
|
|
|
|
|
1. |
Details of the person discharging managerial
responsibilities / person closely associated |
a) |
Name |
Mijke Zachariasse |
2. |
Reason for the notification |
a) |
Position/status |
Member of the Board of Directors |
b) |
Initial notification/Amendment |
Initial notification |
3. |
Details of the issuer, emission allowance market
participant, auction platform, auctioneer or auction
monitor |
a) |
Name |
Genmab A/S |
b) |
LEI-code |
529900MTJPDPE4MHJ122 |
4. |
Details of the transaction(s): section to be repeated for
(i) each type of instrument; (ii) each type of transaction; (iii)
each date; and (iv) each place where transactions have been
conducted |
a) |
Description of the financial instrument, type of instrument
Identification code |
Share DK0010272202 |
b) |
Nature of the transaction |
Acquisition due to vesting of restricted stock units(as employee of
Genmab B.V.) |
c) |
Price(s) and volume(s) |
Price(s) |
Volume(s) |
|
|
DKK 0.00 |
60 |
d) |
Aggregated information - Aggregated volume - Price |
|
e) |
Date of the transaction |
2024-03-01 |
f) |
Place of the transaction |
Outside a market place |
|
|
|
|
|
About Genmab Genmab is an international
biotechnology company with a core purpose guiding its unstoppable
team to strive towards improving the lives of patients through
innovative and differentiated antibody therapeutics. For more than
20 years, its passionate, innovative and collaborative team has
invented next-generation antibody technology platforms and
leveraged translational research and data sciences, which has
resulted in a proprietary pipeline including bispecific T-cell
engagers, next-generation immune checkpoint modulators, effector
function enhanced antibodies and antibody-drug conjugates. To help
develop and deliver novel antibody therapies to patients, Genmab
has formed 20+ strategic partnerships with biotechnology and
pharmaceutical companies. By 2030, Genmab’s vision is to transform
the lives of people with cancer and other serious diseases with
Knock-Your-Socks-Off (KYSO®) antibody medicines.
Established in 1999, Genmab is headquartered in Copenhagen,
Denmark with locations in Utrecht, the Netherlands, Princeton, New
Jersey, U.S. and Tokyo, Japan. For more information, please visit
Genmab.com and follow us on X.com/Genmab.
Contact:
Marisol Peron, Senior Vice President, Global Communications &
Corporate AffairsT: +1 609 524 0065; E: mmp@genmab.com
Andrew Carlsen, Vice President, Head of Investor RelationsT: +45
3377 9558; E: acn@genmab.com
This Company Announcement contains forward looking statements.
The words “believe,” “expect,” “anticipate,” “intend” and “plan”
and similar expressions identify forward looking statements. Actual
results or performance may differ materially from any future
results or performance expressed or implied by such statements. The
important factors that could cause our actual results or
performance to differ materially include, among others, risks
associated with pre-clinical and clinical development of products,
uncertainties related to the outcome and conduct of clinical trials
including unforeseen safety issues, uncertainties related to
product manufacturing, the lack of market acceptance of our
products, our inability to manage growth, the competitive
environment in relation to our business area and markets, our
inability to attract and retain suitably qualified personnel, the
unenforceability or lack of protection of our patents and
proprietary rights, our relationships with affiliated entities,
changes and developments in technology which may render our
products or technologies obsolete, and other factors. For a further
discussion of these risks, please refer to the risk management
sections in Genmab’s most recent financial reports, which are
available on www.genmab.com and the risk factors included in
Genmab’s most recent Annual Report on Form 20-F and other filings
with the U.S. Securities and Exchange Commission (SEC), which are
available at www.sec.gov. Genmab does not undertake any obligation
to update or revise forward looking statements in this Company
Announcement nor to confirm such statements to reflect subsequent
events or circumstances after the date made or in relation to
actual results, unless required by law. Genmab A/S and/or its
subsidiaries own the following trademarks: Genmab®; the Y-shaped
Genmab logo®; Genmab in combination with the Y-shaped Genmab logo®;
HuMax®; DuoBody®; HexaBody®; DuoHexaBody®, HexElect® and KYSO®.
Company Announcement no. 15 CVR no. 2102 3884 LEI Code
529900MTJPDPE4MHJ122
Genmab A/SCarl Jacobsens Vej 302500 Valby Denmark
- 020324_CA15_Managerial Employee Transactions
Genmab AS (TG:GE9)
Historical Stock Chart
Von Mai 2024 bis Jun 2024
Genmab AS (TG:GE9)
Historical Stock Chart
Von Jun 2023 bis Jun 2024